• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatitis: Long-term therapy of chronic hepatitis B reverses cirrhosis.

作者信息

Lok Anna Suk-Fong

出版信息

Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):199-200. doi: 10.1038/nrgastro.2013.13. Epub 2013 Jan 29.

DOI:10.1038/nrgastro.2013.13
PMID:23358397
Abstract
摘要

相似文献

1
Hepatitis: Long-term therapy of chronic hepatitis B reverses cirrhosis.肝炎：慢性乙型肝炎的长期治疗可逆转肝硬化。
Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):199-200. doi: 10.1038/nrgastro.2013.13. Epub 2013 Jan 29.
2
The ether lipid tumour marker in human liver with hepatocellular carcinoma.人类肝细胞癌肝脏中的醚脂肿瘤标志物。
Br J Cancer. 1980 Feb;41(2):320-4. doi: 10.1038/bjc.1980.48.
3
Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression.胰岛素样生长因子II在乙型肝炎、肝硬化及肝细胞癌中的表达：其与乙肝病毒抗原表达的关系
Hepatology. 1994 Oct;20(4 Pt 1):788-99. doi: 10.1002/hep.1840200404.
4
[Expression of MCP/CCR2 in patients of hepatocellular carcinoma and liver cirrhosis].[单核细胞趋化蛋白/趋化因子受体2在肝细胞癌和肝硬化患者中的表达]
Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):553-4.
5
Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States.环氧化酶-2在美国肝细胞癌、肝硬化和慢性肝炎中的表达
Dig Dis Sci. 2007 Jan;52(1):220-7. doi: 10.1007/s10620-006-9184-3. Epub 2006 Dec 8.
6
Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases.血清代谢组学揭示了肝癌和慢性肝病中脂肪酸代谢的失调。
Anal Bioanal Chem. 2012 Apr;403(1):203-13. doi: 10.1007/s00216-012-5782-4. Epub 2012 Feb 14.
7
Differential expression of transforming growth factor alpha and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma.转化生长因子α和胰岛素样生长因子II在慢性活动性乙型肝炎、肝硬化及肝细胞癌中的差异表达
J Hepatol. 1995 Mar;22(3):286-94. doi: 10.1016/0168-8278(95)80281-9.
8
Dynamic metabolic change is indicative of inflammation-induced transformation of hepatic cells.动态代谢变化表明炎症诱导的肝细胞转变。
Int J Biochem Cell Biol. 2015 Sep;66:45-58. doi: 10.1016/j.biocel.2015.07.007. Epub 2015 Jul 20.
9
Snapshot liver transcriptome in hepatocellular carcinoma.肝细胞癌中的肝脏转录组快照
J Hepatol. 2012 Apr;56(4):990-2. doi: 10.1016/j.jhep.2011.08.024. Epub 2011 Dec 13.
10
Digital image analysis of the distribution of proliferating cell nuclear antigen in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma.丙型肝炎病毒相关慢性肝炎、肝硬化和肝细胞癌中增殖细胞核抗原分布的数字图像分析
Dig Dis Sci. 2002 Jul;47(7):1644-8. doi: 10.1023/a:1015800126283.

引用本文的文献

1
Downregulated Expression of Serum Exosome-Derived miR-375-3p Alleviates Interface Hepatitis and Promotes Fibrosis Regression in Patients With Chronic Hepatitis B.血清外泌体来源的miR-375-3p表达下调可减轻慢性乙型肝炎患者的界面性肝炎并促进纤维化消退
Clin Transl Gastroenterol. 2025 May 13;16(7):e00850. doi: 10.14309/ctg.0000000000000850. eCollection 2025 Jul 1.
2
Evaluating the impact of COVID-19 outbreak on hepatitis B and forecasting the epidemiological trend in mainland China: a causal analysis.评估 COVID-19 疫情对乙型肝炎的影响，并预测中国大陆的流行病学趋势：因果分析。
BMC Public Health. 2024 Jan 2;24(1):47. doi: 10.1186/s12889-023-17587-3.
3

本文引用的文献

1
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎时肝硬化的逆转：一项 5 年开放标签随访研究。
Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.
2
Clinical evidence for the regression of liver fibrosis.临床证据表明肝纤维化可逆转。
J Hepatol. 2012 May;56(5):1171-1180. doi: 10.1016/j.jhep.2011.09.024. Epub 2012 Jan 13.
3
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria.
基于 Baveno VII 标准的回顾性研究：HBV 相关肝硬化获得性补偿患者 HCC 风险降低。
Hepatol Commun. 2023 Dec 22;8(1). doi: 10.1097/HC9.0000000000000355. eCollection 2024 Jan 1.
4
Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.新型衣壳组装调节剂的特性及其在慢性乙型肝炎病毒感染治疗中的应用。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0134822. doi: 10.1128/aac.01348-22. Epub 2022 Dec 15.
5
Multiple Facets of Cellular Homeostasis and Regeneration of the Mammalian Liver.哺乳动物肝脏的细胞稳态和再生的多个方面。
Annu Rev Physiol. 2023 Feb 10;85:469-493. doi: 10.1146/annurev-physiol-032822-094134. Epub 2022 Oct 21.
6
The Prognostic Value of Serum HBV-RNA during Hepatitis B Virus Infection is Related to Acute-on-Chronic Liver Failure.血清 HBV-RNA 在乙型肝炎病毒感染中的预后价值与慢加急性肝衰竭相关。
Can J Gastroenterol Hepatol. 2022 Sep 13;2022:8422242. doi: 10.1155/2022/8422242. eCollection 2022.
7
Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.补肾健脾方联合恩替卡韦治疗HBeAg阴性慢性乙型肝炎：一项多中心、随机、双盲、安慰剂对照试验
Evid Based Complement Alternat Med. 2022 Mar 25;2022:6097221. doi: 10.1155/2022/6097221. eCollection 2022.
8
Traditional Chinese medicine Yiqi Huoxue recipe attenuates hepatic fibrosis via YAP/TAZ signaling.中药益气活血方通过YAP/TAZ信号通路减轻肝纤维化。
Histol Histopathol. 2021 Sep;36(9):967-979. doi: 10.14670/HH-18-373. Epub 2021 Sep 7.
9
Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges.代偿期乙型肝炎肝硬化的补偿：现状与挑战。
Biomed Res Int. 2020 Sep 21;2020:9609731. doi: 10.1155/2020/9609731. eCollection 2020.
10
Long-Term Traditional Chinese Medicine Combined with NA Antiviral Therapy on Cirrhosis Incidence in Chronic Hepatitis B Patients in the Real-World Setting: A Retrospective Study.真实世界中慢性乙型肝炎患者长期中医联合核苷（酸）类似物抗病毒治疗对肝硬化发生率的影响：一项回顾性研究
Evid Based Complement Alternat Med. 2020 Aug 3;2020:3826857. doi: 10.1155/2020/3826857. eCollection 2020.
长期使用恩替卡韦治疗可使慢性乙型肝炎患者的纤维化/肝硬化逆转，并持续改善组织学。
Hepatology. 2010 Sep;52(3):886-93. doi: 10.1002/hep.23785.
4
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.成功治疗慢性丙型肝炎患者后丙型肝炎病毒的清除
Gastroenterology. 2008 Sep;135(3):821-9. doi: 10.1053/j.gastro.2008.05.044. Epub 2008 May 21.
5
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.使用阿德福韦酯对HBeAg阴性慢性乙型肝炎进行长达5年的长期治疗。
Gastroenterology. 2006 Dec;131(6):1743-51. doi: 10.1053/j.gastro.2006.09.020. Epub 2006 Sep 20.
6
Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases.经治疗的遗传性血色素沉着症患者肝纤维化的可逆性：36例研究
Hepatology. 2006 Aug;44(2):472-7. doi: 10.1002/hep.21260.
7
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.拉米夫定延长治疗HBeAg阴性慢性乙型肝炎患者
J Hepatol. 2005 Feb;42(2):173-9. doi: 10.1016/j.jhep.2004.10.006.
8
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.非酒精性脂肪性肝病：体重减轻可改善肝脏组织学分析结果
Hepatology. 2004 Jun;39(6):1647-54. doi: 10.1002/hep.20251.
9
Histological outcome during long-term lamivudine therapy.长期拉米夫定治疗期间的组织学结果。
Gastroenterology. 2003 Jan;124(1):105-17. doi: 10.1053/gast.2003.50013.